Stockscreener 앱 받기
3.955
0.00%
0.005
전일 마감가:
$3.96
열려 있는:
$3.95
하루 거래량:
198.97K
Relative Volume:
0.11
시가총액:
$255.66M
수익:
-
순이익/손실:
$-71.17M
주가수익비율:
-2.8453
EPS:
-1.39
순현금흐름:
$-70.97M
1주 성능:
+0.25%
1개월 성능:
+303.83%
6개월 성능:
+40.93%
1년 성능:
-13.16%
1일 변동 폭
$3.95
$3.96
1주일 범위
$3.94
$3.99
52주 변동 폭
$0.721
$6.24
이노즈메 Stock (INZY) Company Profile
명칭
Inozyme Pharma Inc
전화
857-330-4340
주소
321 SUMMER STREET, BOSTON
INZY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INZY
Inozyme Pharma Inc
|
3.96 | 91.68M | 0 | -71.17M | -70.97M | -1.39 |
|
ONC
Beigene Ltd Adr
|
241.57 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
431.80 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.33 | 42.47M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.90 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
72.93 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
이노즈메 Stock (INZY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-12 | 개시 | Raymond James | Outperform |
| 2024-09-12 | 개시 | Stifel | Buy |
| 2024-08-13 | 재개 | Jefferies | Buy |
| 2024-05-30 | 개시 | Wells Fargo | Overweight |
| 2023-03-23 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-05-26 | 개시 | Jefferies | Hold |
| 2022-02-07 | 개시 | H.C. Wainwright | Buy |
| 2021-11-29 | 개시 | Needham | Buy |
| 2020-08-18 | 개시 | BofA Securities | Buy |
| 2020-08-18 | 개시 | Cowen | Outperform |
| 2020-08-18 | 개시 | Piper Sandler | Overweight |
| 2020-08-18 | 개시 | Wedbush | Outperform |
모두보기
이노즈메 주식(INZY)의 최신 뉴스
Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More - Zacks Investment Research
BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz - MSN
BioMarin’s Acquisition of Inozyme Pharma - Global Legal Chronicle
INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc.INZY - Business Wire
BioMarin agrees to acquire Inozyme for $270m - MSN
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
Inozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens - MSN
BioMarin Expands Rare Disease Portfolio with $270M Inozyme Acquisition - MSN
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Inozyme Pharma finds buyer in BioMarin after strategic review - The Business Journals
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Inozyme Pharma, Inc. (Nasdaq – INZY), TXNM Energy, Inc. (NYSETXNM), Servotronics, Inc. (NYSE AmericanSVT), Protagenic Therapeutics, Inc. (Nasdaq – - TradingView
BioMarin: Inozyme Acquisition Falls Short Of Offsetting Looming Revenue Risks (Downgrade) - Seeking Alpha
Piper Sandler Downgrades Inozyme Pharma to Neutral From Overweight, Lowers Price Target to $4 From $23 - marketscreener.com
TD Cowen Downgrades Inozyme Pharma to Hold From Buy, Price Target is $4 - marketscreener.com
Raymond James Downgrades Inozyme Pharma to Market Perform From Outperform - marketscreener.com
BioMarin to acquire Inozyme to enhance its enzyme therapy portfolio - World Pharmaceutical Frontiers
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWTX, NVEE, CHTR, INZY on Behalf of Shareholders - GlobeNewswire Inc.
BioMarin Buying Inozyme Pharma In $270 Million Deal - Pulse 2.0
StockWatch: With Inozyme Buyout, BioMarin Pursues Growth via M&A - Genetic Engineering and Biotechnology News
The week in pharma: action, reaction and insight – week to May 16 - The Pharma Letter
Wells Fargo & Company Reaffirms Equal Weight Rating for Inozyme Pharma (NASDAQ:INZY) - Defense World
Inozyme Pharma (NASDAQ:INZY) Stock Rating Lowered by Wedbush - Defense World
Inozyme Pharma (NASDAQ:INZY) Earns Hold Rating from Jefferies Financial Group - Defense World
BioMarin to buy enzyme therapy developer Inozyme in $270M all-cash deal - MSN
Leerink bullish on BioMarin following Inozyme deal, expects additional BD - Yahoo Finance
Wedbush Has Negative Outlook for Inozyme Pharma Q2 Earnings - Defense World
Inozyme Pharma (INZY) Downgraded by Needham Analyst | INZY Stock News - GuruFocus
Inozyme downgraded to Hold from Buy at TD Cowen - TipRanks
BioMarin to acquire Inozyme for $270 million By Investing.com - Investing.com South Africa
Inozyme Pharma (INZY) Downgraded by Wells Fargo | INZY Stock New - GuruFocus
BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business - insights.citeline.com
Inozyme Pharma (INZY) Downgraded by Wells Fargo | INZY Stock News - GuruFocus
Inozyme stock rating cut to Hold at Jefferies, target to $4 from $15 - Investing.com Nigeria
Inozyme stock rating cut to Hold at Jefferies, target to $4 from $15 By Investing.com - Investing.com South Africa
Inozyme (INZY) Downgraded Following Acquisition Deal | INZY Stoc - GuruFocus
TD Cowen cuts Inozyme stock rating post-acquisition news - Investing.com Australia
TD Cowen cuts Inozyme stock rating post-acquisition news By Investing.com - Investing.com Nigeria
Biomarin snags potential ‘first-in-disease’ ERT in $270M Inozyme buy - BioWorld MedTech
BioMarin’s $270M Inozyme Acquisition Brings Drug That Could Become First for a Rare Disease - MedCity News
Inozyme Pharma (INZY) Sees Price Target Slash and Downgrade by J - GuruFocus
Inozyme Pharma’s Strategic Acquisition by Biomarin: Analyst Holds Rating Amid Favorable Shareholder Outcome and Strategic Alignment - TipRanks
Inozyme (INZY) Downgraded Following Acquisition by BioMarin | INZY Stock News - GuruFocus
Dollar Stock Skyrockets 179% On BioMarin Takeover - Investor's Business Daily
BioMarin stock rises following Inozyme Pharma acquisition By Investing.com - Investing.com Nigeria
BioMarin stock rises following Inozyme Pharma acquisition - Investing.com Australia
BioMarin to acquire Inozyme for $4.00 per share in cash, or $270M - TipRanks
Jefferies Downgrades Inozyme Pharma to Neutral From Buy - marketscreener.com
BioMarin Pharmaceutical: Balancing Opportunities and Risks Amid Inozyme Acquisition and Market Challenges - TipRanks
Jefferies Downgrades Inozyme (INZY) After Acquisition Announceme - GuruFocus
Jefferies Downgrades Inozyme (INZY) After Acquisition Announcement | INZY Stock News - GuruFocus
Inozyme downgraded to Hold from Buy at Jefferies - TipRanks
이노즈메 (INZY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
이노즈메 주식 (INZY) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Treco Douglas A | CEO & Chairman |
Apr 02 '25 |
Sale |
0.89 |
8,819 |
7,849 |
41,046 |
13.67%
자본화:
|
볼륨(24시간):